Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

835 - Current use of clinical nutrition in oncology patients – real world evidence from big data in Italy

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Supportive Care and Symptom Management

Tumour Site

Presenters

Francesco Di Costanzo

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

F. Di Costanzo1, R. Caccialanza2, A. Santoro3, C. Gavazzi4, P. Pedrazzoli5

Author affiliations

  • 1 Sod Medical Oncology, AOU Careggi, 50134 - Firenze/IT
  • 2 Clinical Nutrition And Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, 27100 - Pavia/IT
  • 3 Department Of Medical Oncology And Hematology, Istituto Clinico Humanitas, 20089 - Rozzano/IT
  • 4 Clinical Nutrition Unit, IRCCS Istituto Nationale die Tumori, 20133 - Milano/IT
  • 5 Division Of Medical Oncology, Department Of Hemato-oncology Fondazione Irccs, Policlinico San Matteo, 27100 - Pavia/IT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 835

Background

In cancer patients, research indicates that approximately half of selected patients may suffer from malnutrition. Insufficient nutritional intake, muscle protein depletion and systemic inflammation are key clinical problems. Little is known about the current use of clinical nutrition (CN) in the real world. We set out to investigate the use of CN in patients with metastasized cancer in Italy.

Methods

This observational, retrospective study used an integrated administrative database from 10 Italian Local Health Units covering 5.9 million people. Between 2009 and 2015, CN use, based on Anatomical Therapeutic Chemical Classification codes and ICD-9-CM procedural codes for Enteral/Parenteral Infusion of Concentrated Nutritional Substances and at home nutritional product prescription was examined in patients with metastatic head and neck, gastrointestinal, respiratory, genitourinary or hematologic malignancies (ICD-9-CM diagnosis).

Results

Out of 58,468 metastatic cancer patients with the diagnoses of interest, only 8.2% received clinical nutrition (89% had parenteral nutrition (PN)). Only 4.9% of patients who received CN had concomitant chemotherapy. Among those who received CN, only 11% of patients were diagnosed with malnutrition. The mean time between the diagnosis of metastasis and first use of CN and between the first use of CN and death were 6.6 and 3.5 months, respectively. About half of the patients commenced CN therapy in their last 20 days. Receiving PN was associated with a statistically significant improvement in survival of over 3 months in patients with gastrointestinal and genitourinary cancer who were diagnosed with malnutrition.

Conclusions

CN is under-utilized among cancer patients with metastasis and there is a discrepancy between malnutrition diagnosis rates and uptake of clinical nutrition, which appears to have been used mainly as an end of life measure. Overall, our big data highlights an important unmet need and potential for improved procedures for malnutrition diagnosis and earlier nutritional care, which may improve outcomes of cancer patients.

Clinical trial identification

Legal entity responsible for the study

Baxter S.p.A, Zürich, Switzerland.

Funding

Baxter SA, Zürich, Switzerland.

Editorial Acknowledgement

Medical writing support for this abstract was provided by Anne-Kathrin Fett, IQVIA, Frankfurt, Germany.

Disclosure

F. Di Costanzo, R. Caccialanza, P. Pedrazzoli: Consultant and/or on advisory panel: Baxter Healthcare Corporation. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.